MedTrace Logo

Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients

NCT05380414 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2026-03-31

No results posted yet for this study

Summary

The proposal is to implement a molecular screening program for advanced/metastatic pancreatic cancer patients before the initiation of 1st line treatment in order to allow a better selection of patients for rationale personalized medicine with targeted agents and/or combination involving a chemotherapy backbone.

Conditions

Interventions

BIOLOGICAL

Tumor samples (archival FFPE and optional de novo biopsy) and blood samples

Molecular screening

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Philippe CASSIER, MD, PhD · Centre Leon Berard

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2027-09-01
Completion
2027-09-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05380414 on ClinicalTrials.gov